Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Nasuh C. Buyukkaramikli*, Hedwig M. Blommestein, Rob Riemsma, Nigel Armstrong, Fiona J. Clay, Janine Ross, Gill Worthy, Johan Severens, Jos Kleijnen, Maiwenn J. Al

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Original languageEnglish
Pages (from-to)1211-1221
Number of pages11
JournalPharmacoeconomics
Volume35
Issue number12
DOIs
Publication statusPublished - Dec 2017

Keywords

  • HEALTH STATE UTILITIES
  • RANDOMIZED PHASE-III
  • SUPPORTIVE CARE
  • OPEN-LABEL
  • TRIAL
  • IRINOTECAN
  • PLUS
  • COMBINATION
  • MONOTHERAPY
  • PACLITAXEL

Cite this